See more : Cornerstone Technologies Holdings Limited (8391.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Gufic Biosciences Limited (GUFICBIO.BO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Gufic Biosciences Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Digital Transformation Opportunities Corp. (DTOC) Income Statement Analysis – Financial Results
- Electric Power Development Co., Ltd. (EDRWY) Income Statement Analysis – Financial Results
- DHI Group, Inc. (DHX) Income Statement Analysis – Financial Results
- Imperial Brands PLC (IMB.L) Income Statement Analysis – Financial Results
- China Everbright Bank Company Limited (601818.SS) Income Statement Analysis – Financial Results
Gufic Biosciences Limited (GUFICBIO.BO)
About Gufic Biosciences Limited
Gufic Biosciences Limited manufactures and markets active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India, Africa, Asia, Europe, Australia, North America, South America, and internationally. The company manufactures APIs and bulk drugs, such as antifungals, anesthetics, immuno suppressants, and intermediates for antifungals. It manufactures lyophilized injections, which include antibiotic, antifungal, cardiac, infertility, antiviral, and proton-pump inhibitor segments. In addition, the company offers spark, criti care, criticare life, and ferticare pharmaceutical products; and herbal, aesthaderm, gufic stridden, and personal care products. It supplies its products to hospital chains and medical facilities. Gufic Biosciences Limited was founded in 1970 and is based in Mumbai, India.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 8.07B | 6.91B | 7.79B | 4.88B | 3.79B | 3.51B | 3.06B | 2.46B | 2.02B | 1.52B | 1.23B | 1.00B | 835.65M | 714.65M | 628.86M | 516.84M | 540.94M |
| Cost of Revenue | 5.66B | 3.32B | 4.12B | 2.58B | 1.87B | 1.82B | 1.45B | 1.23B | 1.04B | 827.33M | 674.72M | 519.60M | 458.19M | 369.40M | 340.50M | 281.08M | 334.83M |
| Gross Profit | 2.41B | 3.59B | 3.67B | 2.30B | 1.92B | 1.69B | 1.60B | 1.22B | 977.31M | 688.19M | 555.39M | 481.85M | 377.46M | 345.25M | 288.36M | 235.76M | 206.11M |
| Gross Profit Ratio | 29.85% | 51.95% | 47.13% | 47.15% | 50.64% | 48.16% | 52.46% | 49.83% | 48.33% | 45.41% | 45.15% | 48.12% | 45.17% | 48.31% | 45.85% | 45.62% | 38.10% |
| Research & Development | 54.13M | 51.56M | 44.29M | 20.99M | 20.01M | 20.78M | 52.88M | 15.29M | 6.81M | 2.58M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 185.92M | 149.01M | 142.61M | 92.03M | 74.31M | 67.79M | 61.66M | 67.10M | 59.55M | 38.58M | 26.46M | 17.37M | 19.97M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 21.23M | 59.56M | 33.44M | 18.57M | 37.07M | 17.31M | 13.25M | 965.00K | 5.73M | 7.46M | 62.49M | 138.55M | 107.83M | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.06B | 822.83M | 176.06M | 110.60M | 111.38M | 85.10M | 74.92M | 68.07M | 65.28M | 46.04M | 88.95M | 155.91M | 127.80M | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Expenses | -2.38M | 25.74M | 31.04M | 2.74M | 33.00M | 20.92M | 15.61M | 2.04M | 1.85M | 2.53M | 2.00M | 293.00K | 42.00K | 1.52M | 0.00 | 386.67K | 0.00 |
| Operating Expenses | 1.08B | 2.46B | 2.38B | 1.62B | 1.52B | 1.27B | 1.26B | 1.03B | 811.99M | 579.56M | 458.42M | 389.66M | 321.16M | 304.11M | 249.29M | 193.18M | 171.91M |
| Cost & Expenses | 6.74B | 5.78B | 6.50B | 4.20B | 3.39B | 3.09B | 2.71B | 2.26B | 1.86B | 1.41B | 1.13B | 909.26M | 779.35M | 673.52M | 589.79M | 474.26M | 506.75M |
| Interest Income | 14.12M | 14.12M | 18.79M | 14.51M | 13.64M | 10.01M | 6.15M | 6.52M | 2.56M | 1.10M | 1.12M | 927.00K | 147.00K | 97.00K | 265.18K | 151.86K | 248.59K |
| Interest Expense | 153.60M | 82.23M | 53.66M | 117.66M | 126.79M | 100.26M | 86.60M | 62.15M | 61.26M | 44.31M | 38.90M | 31.84M | 21.29M | 18.12M | 18.96M | 26.23M | 18.84M |
| Depreciation & Amortization | 170.17M | 222.81M | 171.34M | 163.08M | 138.65M | 46.47M | 44.00M | 36.83M | 37.87M | 38.52M | 24.68M | 21.80M | 18.81M | 18.07M | 16.63M | 16.73M | 18.04M |
| EBITDA | 1.47B | 1.37B | 1.48B | 876.52M | 579.04M | 489.98M | 435.03M | 239.29M | 203.46M | 148.39M | 126.57M | 111.33M | 70.70M | 59.20M | 52.52M | 59.31M | 52.11M |
| EBITDA Ratio | 18.25% | 19.87% | 19.40% | 17.58% | 14.95% | 14.25% | 13.56% | 9.88% | 10.00% | 9.77% | 10.27% | 10.72% | 8.27% | 8.28% | 8.86% | 11.48% | 9.66% |
| Operating Income | 1.31B | 1.18B | 1.29B | 684.67M | 400.87M | 417.35M | 346.87M | 174.00M | 108.31M | 60.65M | 57.60M | 49.70M | 26.18M | 22.18M | 16.94M | 17.18M | 15.61M |
| Operating Income Ratio | 16.26% | 17.04% | 16.61% | 14.04% | 10.58% | 11.90% | 11.35% | 7.09% | 5.36% | 4.00% | 4.68% | 4.96% | 3.13% | 3.10% | 2.69% | 3.32% | 2.89% |
| Total Other Income/Expenses | -154.82M | -86.10M | -25.99M | -107.55M | -94.92M | -66.88M | -47.16M | -30.32M | -62.54M | -40.11M | -31.95M | -35.61M | -21.16M | -20.69M | -18.38M | -19.56M | -375.90K |
| Income Before Tax | 1.16B | 1.07B | 1.27B | 577.12M | 301.26M | 353.49M | 299.54M | 143.67M | 103.58M | 65.26M | 62.73M | 52.63M | 29.70M | 23.70M | 16.94M | 17.18M | 15.61M |
| Income Before Tax Ratio | 14.34% | 15.45% | 16.28% | 11.83% | 7.95% | 10.08% | 9.80% | 5.85% | 5.12% | 4.31% | 5.10% | 5.26% | 3.55% | 3.32% | 2.69% | 3.32% | 2.89% |
| Income Tax Expense | 295.36M | 270.16M | 309.98M | 134.80M | 74.38M | 134.08M | 134.78M | 53.47M | 30.34M | 23.69M | 20.09M | 19.34M | 14.43M | 9.06M | 4.66M | 8.81M | 6.84M |
| Net Income | 861.36M | 797.05M | 958.40M | 442.32M | 226.88M | 219.41M | 164.76M | 90.21M | 73.24M | 41.58M | 42.64M | 33.29M | 15.27M | 14.64M | 12.28M | 8.36M | 8.77M |
| Net Income Ratio | 10.68% | 11.54% | 12.30% | 9.07% | 5.99% | 6.26% | 5.39% | 3.67% | 3.62% | 2.74% | 3.47% | 3.32% | 1.83% | 2.05% | 1.95% | 1.62% | 1.62% |
| EPS | 8.74 | 8.22 | 9.89 | 4.56 | 2.34 | 2.82 | 2.12 | 1.17 | 0.95 | 0.54 | 0.55 | 0.43 | 0.20 | 0.19 | 0.16 | 0.11 | 0.11 |
| EPS Diluted | 8.74 | 8.22 | 9.89 | 4.56 | 2.34 | 2.82 | 2.12 | 1.17 | 0.95 | 0.54 | 0.55 | 0.43 | 0.20 | 0.19 | 0.16 | 0.11 | 0.11 |
| Weighted Avg Shares Out | 98.55M | 96.94M | 96.94M | 96.94M | 96.94M | 77.83M | 77.83M | 77.35M | 77.35M | 77.35M | 77.35M | 77.35M | 77.35M | 77.35M | 77.35M | 77.35M | 77.35M |
| Weighted Avg Shares Out (Dil) | 98.55M | 96.94M | 96.94M | 96.94M | 96.94M | 77.83M | 77.83M | 77.35M | 77.35M | 77.35M | 77.35M | 77.35M | 77.35M | 77.35M | 77.35M | 77.35M | 77.35M |
Source: https://incomestatements.info
Category: Stock Reports